{"nctId":"NCT01991821","briefTitle":"European Phase III Study of APD421 in PONV","startDateStruct":{"date":"2013-07"},"conditions":["PONV"],"count":368,"armGroups":[{"label":"APD421","type":"EXPERIMENTAL","interventionNames":["Drug: APD421"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"APD421","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age\n* Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure and expected to require at least one overnight stay in hospital\n\nExclusion Criteria:\n\n* Patients scheduled for outpatient/day case surgery\n* Patients scheduled to undergo intra-thoracic, transplant or central nervous system surgery\n* Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block\n* Patients who are expected to remain ventilated for a period after surgery\n* Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Response (no Emesis, Significant Nausea or Rescue Medication)","description":"The primary efficacy analysis was a comparison of the incidence of Complete Response (absence of PONV1) in the 0-24-hour period after surgery, between the active treatment group and the placebo group using Pearson square test with Yates's continuity correction at a two-sided significance level of 5%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response (no Emesis or Rescue Medication)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Response (no Emesis, Nausea or Rescue Medication)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Emesis (Vomiting/Retching)","description":"An assessment of a participant experiencing an episode of emesis (vomiting/ retching) or received anti-emetic rescue medication during the 24hours after the completion of the surgery","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Nausea","description":"Count of patients experiencing an episode of nausea scored ≥ 1 of 0-10 verbal response scale during the 24 hours period after the completion of surgery","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Significant Nausea","description":"Count of participants with nausea score ≥ 4 on 0-10 verbal response scale","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":169},"commonTop":["Procedural Pain","Nausea","Flatulence","Constipation","Hypotension"]}}}